Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease By Brandon Tilley|2023-06-22T18:16:59+00:00February 25, 2021|News|0 Comments Read More
Restoring IL-2 to its cancer immunotherapy glory By webadmin@biolojic.com|2024-08-26T10:48:45+00:00February 18, 2021|News|0 Comments Read More
